Long-term safety of daclizumab beta in patients with relapsing MS in EXTEND: interim results from treatment up to 6 years

Authors

• Stanley Cohan, Providence Multiple Sclerosis Center, USA.Follow

Document Type

Presentation

Publication Date

2018

Keywords

oregon; providence neuroscience institute

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences